N4 PHARMA PLC — Major Shareholding Notification 2016

Aug 3, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1047G

Verona Pharma PLC

03 August 2016

i

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii		Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii	Vivo Ventures VII, LLC
4. Full name of shareholder(s) (if different from 3.):iv	Vivo Ventures fund VII, LP Vivo Ventures VII Affiliates Fund, LP
5. Date of the transaction and date on which the threshold is crossed or reached: v	July 29, 2016
6. Date on which issuer notified:	July 29, 2016
7. Threshold(s) that is/are crossed or reached: vi, vii	6.5% to 9.84% Change at Combined Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of  voting rights x
Direct	Direct xi	Indirect xii	Direct	Indirect
GB00B06GSH43	65,600,000	65,600,000	252,393,874		252,393,874		9.84%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date xiii	Exercise/ Conversion Period xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
252,393,874	9.84%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII) and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII, LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates Fund VII beneficially own 247,010,316 and 5,383,558 shares of Common Stock respectively.

Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Vivo Capital, LLC Attn: Cinthia Sheu
15. Contact telephone number:	+1-650-688-0818

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUGURPRUPQUMW